Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of senkyunolide I in sepsis lung injury treatment medicine

A technology of chuanxiong lactone and therapeutic drugs, which is applied in the field of medicine and biology, can solve the problems that it is difficult to accurately describe the therapeutic effect of a single molecule and increase the incidence of adverse drug reactions, so as to inhibit platelet activation, reduce adverse drug reactions, and reduce the incidence Effect

Inactive Publication Date: 2021-09-21
中国人民解放军海军军医大学第一附属医院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It can be seen that the existing therapeutic drugs are mixed with many different compounds, it is difficult to accurately describe the therapeutic effect of a single molecule, and the increase of molecular components may increase the incidence of adverse drug reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of senkyunolide I in sepsis lung injury treatment medicine
  • Application of senkyunolide I in sepsis lung injury treatment medicine
  • Application of senkyunolide I in sepsis lung injury treatment medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] This example provides the application of Liguscaractone I in the treatment of septic lung injury.

[0028] The drug for treating sepsis lung injury includes ligustilide I and a pharmaceutically acceptable carrier.

[0029] The percentage by weight of ligustilide I in the drug for treating sepsis lung injury is 0.1-99.9%.

[0030] The chemical structure of ligustilide I is as follows:

[0031]

[0032] Its molecular formula is C 12 h 16 o 4 , the molecular weight is 224.256.

[0033] The drug dosage forms for the treatment of sepsis lung injury are tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, buccal preparations, granules, granules, Any one of pills, powders, ointments, elixirs, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops and patches.

[0034] That is to say, the drug dosage form for the treatment of sepsis lung injury c...

Embodiment 2

[0047] This example is a pharmacodynamic study on the therapeutic effect of ligustilide I on the sepsis animal model on sepsis lung injury.

[0048] 2.1 Experimental materials

[0049] 48 male clean-grade C57BL / 6 mice were divided into 4 groups, 12 in each group, 22-25g, ligustonin I (purchased from Shanghai Zheyan Biotechnology Co., Ltd.), sevoflurane, dimethyl sulfoxide , hematoxylin and eosin stain, BCA kit, MPO fluorescent antibody.

[0050] 2.2 Experimental method

[0051] After the mice were anesthetized with sevoflurane, they were laparotomed through a midline abdominal incision, the cecum was exposed, ligated at 1 / 2 of the cecum, and pierced with a 22G needle. A small amount of intestinal content was squeezed out and the abdomen was closed layer by layer. In the control group, the cecum was exposed in the same manner but the cecum was not ligated or perforated. The experimental mice were divided into sham operation dimethyl sulfoxide group, sham operation ligustonin...

Embodiment 3

[0061] This example is a pharmacodynamic study on the inhibitory effect of ligustilide I on lung tissue inflammatory factors and oxidative stress levels in a sepsis animal model.

[0062] 3.1 Experimental materials

[0063] 24 male clean-grade C57BL / 6 mice were divided into 4 groups, 6 mice in each group, 22-25g, ligustonin I (purchased from Shanghai Zheyan Biotechnology Co., Ltd.), sevoflurane, dimethyl sulfoxide , TNF-α, IL-1β, IL-6 ELISA kit, MDA kit.

[0064] 3.2 Experimental method

[0065] After the mice were anesthetized with sevoflurane, they were laparotomed through a midline abdominal incision, the cecum was exposed, ligated at 1 / 2 of the cecum, and pierced with a 22G needle. A small amount of intestinal content was squeezed out and the abdomen was closed layer by layer. In the control group, the cecum was exposed in the same manner but the cecum was not ligated or perforated. The experimental mice were divided into sham operation dimethyl sulfoxide group, sham op...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of senkyunolide I in a sepsis lung injury treatment medicine, and belongs to the technical field of medical biology. The senkyunolide I has the effects of inhibiting inflammatory cytokines and oxidative stress level in the medicine for treating the sepsis lung injury, and has the effect of inhibiting platelet activation in the medicine for treating the sepsis lung injury. The senkyunolide I has the effect of inhibiting the formation of a neutrophil extracellular capture net in the sepsis lung injury treatment medicine.

Description

technical field [0001] The invention belongs to the technical field of medicine and biotechnology, and in particular relates to the application of chuanxiong lactone I in a medicine for treating sepsis lung injury. Background technique [0002] Sepsis refers to organ dysfunction caused by infection, specifically the clinical process of systemic inflammatory response triggered by bacterial infection, and is a common complication after surgery in critically ill patients, and is one of the important causes of death in clinical critically ill patients. The lung is the organ most commonly involved in sepsis and the most vulnerable target organ. Septic lung injury produces pulmonary inflammation and oxidative stress, as well as activation of pulmonary platelets and formation of neutrophil extracellular traps. Oxygen therapy and mechanical ventilation are currently the most commonly used techniques for the treatment of septic lung injury, but the therapeutic drugs for this disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61K36/236A61P11/00A61P31/04
CPCA61K31/365A61K36/236A61P11/00A61P31/04
Inventor 王嘉锋解健朱成龙李鹏赵珍珍邓小明
Owner 中国人民解放军海军军医大学第一附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com